Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

Cancer Discov. 2024 Dec 2;14(12):2407-2429. doi: 10.1158/2159-8290.CD-24-0190.

Abstract

This study reveals that Fc-enhanced anti-CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti-CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a new class of immuno-oncology agents, capable of extending clinical benefit to patients with cancers resistant to current immunotherapies.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • CTLA-4 Antigen* / antagonists & inhibitors
  • Cell Line, Tumor
  • Humans
  • Immunoglobulin Fc Fragments / therapeutic use
  • Immunotherapy* / methods
  • Mice
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • Neoplasms / therapy

Substances

  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • Immunoglobulin Fc Fragments